HRMY MEXC RealStocks
Own real HRMY shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 12:24:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Harmony Biosciences Holdings, Inc. (HRMY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $33.90, with a market capitalization of $1.98B and a P/E ratio of 11.11. Over the past 52 weeks, its price has ranged from $25.90 to $43.49. This page covers its latest market performance, valuation, price trends and company information.
$1.98B | |
$33.80 | |
$33.90 | |
$33.35 | |
$33.80 | |
1.64K | |
999.66K | |
11.11 | |
$43.49 | |
$25.90 | |
-- | |
-- |
Harmony Biosciences Holdings, Inc. (HRMY) is trading at $33.90 in pre-market trading as of 2026-11-13 12:10:00, up 0.30% ($0.10) from the previous close of $33.80
Pre-market trading shows how investors are pricing HRMY before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Harmony Biosciences Holdings, Inc. (HRMY) moved from $32.47 to $33.90, representing a gain of 4.40% ($1.43).
The stock traded between $32.27 and $35.68 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 898.86 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 45.5%
HRMY is currently trading at $33.90, placing it 45.5% of the way from its 52-week low of $25.90 to its 52-week high of $43.49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 293 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Harmony Biosciences Holdings, Inc. (HRMY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to HRMY, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between HRMY shares and USD.
HRMY Shares to USD
1.00 HRMY shares = 33.9 USD
Calculations are estimates based on the latest available price and are for reference only.